Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(33%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
4
67%
Ph not_applicable
1
17%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Other(2)

Detailed Status

Recruiting2
Completed2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 21 (16.7%)
N/A1 (16.7%)

Trials by Status

recruiting233%
completed233%
unknown233%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_1

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

NCT06557265
recruitingphase_1

HRYZ-T101 Injection for HPV18 Positive Solid Tumor

NCT05952947
unknownphase_1

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

NCT05787535
unknownphase_1

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

NCT05122221
completedphase_2

A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

NCT00597519
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06557265Phase 1

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Recruiting
NCT05952947Phase 1

HRYZ-T101 Injection for HPV18 Positive Solid Tumor

Recruiting
NCT05787535Phase 1

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

Unknown
NCT05122221Phase 1

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

Unknown
NCT00597519Phase 2

A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

Completed
NCT00186797Not Applicable

Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6